non-metastatic castration-resistant prostate cancer – Talk Bio

Actionable Insights Powered by AI

Comparative Efficacy of J&J’s Erleada and Astellas/Pfizer’s Xtandi in Non-Metastatic Prostate Cancer: Real-World Study Insights

7 months ago talkbio0Tagged apalutamide, Comparative Efficacy, enzalutamide, Erleada, Malignant neoplasm of prostate, nmCRPC, non-metastatic castration-resistant prostate cancer, profiles, Real-World Study, Safety

Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), Erleada (Apalutamide), Xtandi (Enzalutamide), Real-World Study, Comparative Efficacy, Safety Profiles

Bayer’s NUBEQA Shows Promise in Prostate Cancer Treatment, Expanding Indications

9 months ago talkbio0Tagged ARAMIS, ARASENS, Bayer, Clinical Trials, Corporation, darolutamide, Hormone Responsive, Malignant neoplasm of prostate, Metastatic to, non-metastatic castration-resistant prostate cancer, Nubeqa, Orion

NUBEQA, darolutamide, prostate cancer, metastatic hormone-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, ARASENS trial, ARAMIS trial, Bayer, Orion Corporation